Xb130 expression in human osteosarcoma: A clinical and experimental study

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 3, 2015, Pages 2565-2573

  Wang, Xiaohui ^a   Wang, Ruiguo ^b   Liu, Zhaolong ^c   Hao, Fengyun ^d   Huang, Hai ^e   Guo, Wenchen ^f  

^a Department of Orthopedics Central Hospital of Yishui   (China)

^b Rizhao Hospital of TCM   (China)

^c PEOPLE S HOSPITAL OF RIZHAO   (China)

^d QINGDAO UNIVERSITY   (China)

^e LINYI PEOPLE'S HOSPITAL   (China)

^f WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

Immunohistochemistry; Osteosarcoma; Prognosis; RNA interference; Xb130

Indexed keywords

AFAP1L2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; ANIMAL; BIOSYNTHESIS; BONE TUMOR; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; MOUSE; NUDE MOUSE; OSTEOSARCOMA; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; WESTERN BLOTTING; XENOGRAFT; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; ANIMALS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BONE NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, NUDE; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TRANSFECTION; YOUNG ADULT;

EID: 84933034759     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Miiji LN, Petrilli AS, Di Cesare S, Odashiro AN, Burnier MN Jr, de Toledo SR, Garcia RJ, Alves MT. C-kit expression in human osteosarcoma and in vitro assays. Int J Clin Exp Pathol 2011; 4: 775-81.
2. Unni KK. Osteosarcoma. In: Unni KK, editor. Dahlin's bone tumors. 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2010. pp. 122-57.
3. Bacci G, Ferrari S, Longhi A, Forni C, Zavatta M, Versari M, Smith K. High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol 2002; 24: 27-30.
4. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus Garcia R, Camargo OP, Pena W, Péricles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Al-meida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006; 24: 1161-1168.
5. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11: 449-453.
6. Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, Campanacci M. P-glycoprotein expression in osteosarcoma: a basis for risk adapted adjuvant chemotherapy. J Orthop Res 1999; 17: 629-632.
7. Benassi MS, Molendini L, Gamberi G, Sollazzo MR, Ragazzini P, Merli M, Magagnoli G, San-giorgi L, Bacchini P, Bertoni F, Picci P: Altered G1 phase regulation in osteosarcoma. Int J Cancer 1997; 74: 518-522.
8. Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010; 10: 271-87.
9. Magnan H, Chou AJ, Chou JF, Yeung HW, Healey JH, Meyers PA. Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma. Cancer 2010; 116: 4147-51.
10. Shiozaki A, Liu M. Roles of XB130, a novel adaptor protein, in cancer. J Clin Bioinforma 2011; 1: 10.
11. Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, Kitagawa M, Nakou Y, Kishimoto M, Liu M, Otsuji E. XB130 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2012; 20: 3140-50.
12. Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T. XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol 2011; 178: 391-401.
13. Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, Wang N, Wu Y, Liao Y, Liao W. Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One 2012; 7: e41660.
14. Zuo Q, Huang H, Shi M, Zhang F, Sun J, Bin J, Liao Y, Liao W. Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec (Hoboken) 2012; 295: 423-31.
15. Sobin LH, Wittekind C. UICC-TNM Classificaton of Malignant Tumors. New York: Wiley; 2002.
16. Xu J, Bai XH, Lodyga M, Han B, Xiao H. XB130, a novel adaptor protein for signal transduction. J Biol Chem 2007; 282: 16401-16412.
17. Lodyga M, Bai XH, Kapus A, Liu M. Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion. J Cell Sci 2010; 123: 4156-69.
18. Zhang J, Jiang X, Zhang J. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma. World J Surg Oncol 2014; 12: 49